| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2017-10-03 |
| タイトル |
|
|
タイトル |
In vivo immunological antitumor effect of OK-432-stimulated dendritic cell transfer after radiofrequency ablation |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| ID登録 |
|
|
ID登録 |
10.24517/00013624 |
|
ID登録タイプ |
JaLC |
| 著者 |
Nakagawa, Hidetoshi
Mizukoshi, Eishiro
Iida, Noriho
Terashima, Takeshi
Kitahara, Masaaki
Marukawa, Yohei
Kitamura, Kazuya
Nakamoto, Yasunari
Hiroishi, Kazumasa
Imawari, Michio
Kaneko, Shuichi
|
| 著者別表示 |
中河, 秀俊
水腰, 英四郎
飯田, 宗穂
寺島, 健志
北原, 征明
北村, 和哉
中本, 安成
金子, 周一
|
| 提供者所属 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
金沢大学先進予防医学研究センター / 金沢大学医薬保健研究域医学系 |
| 書誌情報 |
Cancer Immunology, Immunotherapy
巻 63,
号 4,
p. 347-356,
発行日 2014-04-01
|
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
0340-7004 |
| NCID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA00598499 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1007/s00262-013-1514-7 |
| 出版者 |
|
|
出版者 |
Springer-Verlag |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Radiofrequency ablation therapy (RFA) is a radical treatment for liver cancers and induces tumor antigen-specific immune responses. In the present study, we examined the antitumor effects of focal OK-432-stimulated dendritic cell (DC) transfer combined with RFA and analyzed the functional mechanisms involved using a murine model. C57BL/6 mice were injected subcutaneously with colon cancer cells (MC38) in their bilateral flanks. After the establishment of tumors, the subcutaneous tumor on one flank was treated using RFA, and then OK-432-stimulated DCs were injected locally. The antitumor effect of the treatment was evaluated by measuring the size of the tumor on the opposite flank, and the immunological responses were assessed using tumor-infiltrating lymphocytes, splenocytes and draining lymph nodes. Tumor growth was strongly inhibited in mice that exhibited efficient DC migration after RFA and OK-432-stimulated DC transfer, as compared to mice treated with RFA alone or treatment involving immature DC transfer. We also demonstrated that the antitumor effect of this treatment depended on both CD8-positive and CD4-positive cells. On the basis of our findings, we believe that combination therapy for metastatic liver cancer consisting of OK-432-stimulated DCs in combination with RFA can proceed to clinical trials, and it is anticipated to be markedly superior to RFA single therapy. © 2013 Springer-Verlag Berlin Heidelberg. |
| 著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
ME-PR-KANEKO-S-347.pdf (1.5 MB)
.png)
